US Cancer Centers Face Critical Shortages of Essential Treatment Drugs

Cancer treatment centers across the United States are continuing to deal with shortages of essential medicines, raising concerns about treatment delays, additional pressure on healthcare providers and the ability of hospitals to maintain recommended care for patients.

A new survey involving more than 30 academic cancer treatment facilities found that every center surveyed was experiencing a shortage of at least one anti-cancer medicine. More than one in five facilities reported shortages involving five or more different cancer drugs.

The findings highlight the continuing challenges surrounding the US cancer drug supply and the potential impact on patients who depend on chemotherapy, immunotherapy and other established treatments.

Cancer Drug Shortages Continue Across the US

The latest survey indicates that drug shortages remain a significant issue for cancer treatment centers despite years of concern from healthcare professionals and medical organisations.

The shortages affect medicines used to treat several types of cancer, including lung, ovarian, bladder, uterine, breast and testicular cancers. Some of the medicines affected are used across multiple cancer types, meaning that supply problems can have an impact far beyond a single group of patients.

According to the report, 94 percent of surveyed centers experienced a shortage of multi-use ifosfamide. Carboplatin was in short supply at 71 percent of centers, while 16 percent reported shortages involving cisplatin.

These medicines can play an important role in established cancer treatment plans. When supplies become limited, medical teams may need to spend additional time finding alternatives, adjusting treatment schedules or managing available supplies.

Which Cancer Drugs Are in Short Supply?

Several widely used medicines were highlighted in the survey.

Ifosfamide: This chemotherapy medicine is used to treat several cancers, including certain forms of lung cancer and other malignancies. The survey found that it was among the most commonly affected drugs, with 94 percent of participating centers reporting a shortage of the multi-use formulation.

Carboplatin: Carboplatin is a chemotherapy medicine used in the treatment of several cancers, including ovarian cancer. Around 71 percent of surveyed centers reported a shortage.

Cisplatin: Another widely used chemotherapy medicine, cisplatin is used in the treatment of bladder cancer as well as several other cancers. The survey found that 16 percent of centers were experiencing a shortage.

Bacillus Calmette-Guérin: Often referred to as BCG, this immunotherapy is used in the treatment of bladder cancer. More than half of the survey respondents reported that this medicine was in short supply.

Because these medicines can be used for different types of cancer, shortages can create complex challenges for healthcare teams attempting to maintain treatment plans.

Shortages Can Put Additional Pressure on Cancer Care

Drug shortages do not necessarily mean that every patient will be unable to receive treatment. Cancer centers have developed strategies to manage limited supplies and keep patients receiving recommended therapies wherever possible.

However, these measures can require considerable additional time and resources.

The survey found that 61 percent of participating centers required mitigation strategies to help patients remain on recommended doses. Such strategies can include managing existing stock carefully, identifying alternative treatment options and coordinating supplies.

For patients and their families, uncertainty surrounding medication availability can add another layer of stress during an already difficult period.

Healthcare professionals can also face additional administrative responsibilities as they attempt to ensure that appropriate medicines remain available.

Insurance Authorizations Add to the Challenge

The problem is not limited to the physical availability of cancer medicines.

According to the survey, 90 percent of cancer centers reported needing multiple authorizations from health insurance companies when managing treatment affected by drug shortages.

Additional authorization requirements can increase administrative workload and potentially contribute to delays in care. When a standard medicine is unavailable, a healthcare team may need to consider another treatment option. That alternative may then require approval before it can be provided.

This creates another potential barrier for patients and medical teams who are already dealing with an uncertain drug supply.

Calls for Changes to US Drug Production

The National Comprehensive Cancer Network has identified several potential approaches to reducing cancer drug shortages.

Among the proposed solutions are changes to federal drug production policies designed to make medicine supplies more stable. The organisation has also called for greater incentives for domestic manufacturing.

The broader issue is that maintaining a reliable supply of essential medicines requires manufacturers, regulators, healthcare organisations and policymakers to work together.

A stable domestic production system could potentially reduce vulnerabilities in the supply chain and make it easier to respond when shortages occur.

Legislation has also been introduced in an effort to address drug shortages, although the measures discussed in the report had not yet passed.

Government and FDA Response

US government agencies are also working to address the ongoing shortages.

The Food and Drug Administration said it was aware of shortages involving ifosfamide and concerns surrounding the supply of cisplatin and carboplatin. The agency said it was working with manufacturers and other stakeholders to understand supply constraints and identify ways to increase availability.

The FDA also reported that it had exercised regulatory discretion to allow imports of ifosfamide to provide additional supply.

Temporary imports can be used as one way of bridging gaps when domestic supplies are insufficient. However, longer-term solutions may be needed to prevent recurring shortages of essential medicines.

Why Cancer Drug Supply Matters

The continuing shortages are particularly concerning because cancer remains one of the leading causes of death in the United States.

The American Cancer Society projected that more than 626,000 people would die from cancer in the US during 2026. With hundreds of thousands of people expected to die from the disease, reliable access to established treatments remains a major healthcare priority.

At the same time, cancer care continues to evolve. Researchers are developing new medicines, immunotherapies and personalised treatment approaches that could expand the range of options available to patients.

However, newer treatments do not eliminate the importance of established medicines. Many widely used chemotherapy drugs remain an important part of treatment for different cancers.

What Happens Next?

The latest survey suggests that cancer drug shortages remain a serious issue for US healthcare providers.

Although cancer centers have developed strategies to manage shortages, these approaches can require additional administrative work and may place further pressure on patients, doctors, pharmacists and healthcare systems.

Improving the reliability of drug manufacturing, strengthening supply chains and reducing avoidable administrative barriers could all play a role in improving access to essential cancer medicines.

For now, healthcare providers continue to manage shortages while government agencies and policymakers consider longer-term solutions.

The situation also demonstrates why medicine supply chains are an important part of cancer care. Effective cancer treatment depends not only on medical research and skilled healthcare professionals, but also on ensuring that essential medicines are available when patients need them.

Source disclaimer: The Independent, including findings attributed to a survey of more than 30 academic cancer centers and statements from the National Comprehensive Cancer Network and the US Food and Drug Administration. The article is intended for informational purposes and should not be considered medical advice. Readers should consult qualified healthcare professionals or authoritative medical organisations for advice about cancer treatment, medicines or individual health circumstances.